[Serevent. Salmeterolxinafoate].
Madl
M L
ML
Glaxo Pharmazeutika Gesellschaft m. b. H., Wien.
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D001317:Austria; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068299:Salmeterol Xinafoate
D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol
Serevent. Salmeterol Xinafoat.